Lonza Group AG
LONN | SW
Overview
Corporate Details
- ISIN(s):
- CH0013841017 (+2 more)
- LEI:
- 549300EFW4H2TCZ71055
- Country:
- Switzerland
- Address:
- MÜNCHENSTEINERSTR. 38, 4052 BASEL
- Website:
- https://www.lonza.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Lonza Group is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-23 06:30 |
Earnings Release
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sale…
|
English | 42.2 KB | |
| 2025-07-23 02:00 |
Earnings Release
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sale…
|
English | 37.0 KB | |
| 2025-07-23 02:00 |
Earnings Release
Lonza erzielt starkes Ergebnis im ersten Halbjahr 2025 und erhöht Umsatz- und M…
|
German | 36.9 KB | |
| 2025-05-27 07:00 |
Earnings Release
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Stru…
|
English | 12.7 KB | |
| 2025-05-27 02:00 |
Regulatory News Service
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Stru…
|
English | 9.7 KB | |
| 2025-05-15 09:00 |
Board/Management Information
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
|
English | 14.6 KB | |
| 2025-05-15 02:00 |
Board/Management Information
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
|
English | 11.0 KB | |
| 2025-05-10 16:30 |
Post-Annual General Meeting Information
Lonza Announces Results of the 2025 Annual General Meeting All Motions Propose…
|
English | 16.3 KB | |
| 2025-05-09 06:30 |
Earnings Release
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in L…
|
English | 15.2 KB | |
| 2025-05-09 02:00 |
Earnings Release
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in L…
|
English | 12.5 KB | |
| 2025-04-03 07:00 |
Report Publication Announcement
Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual a…
|
English | 20.1 KB | |
| 2025-04-02 14:00 |
Regulatory News Service
Lonza Implements its Simplified and Streamlined Operating Model
|
English | 16.3 KB | |
| 2025-04-01 07:00 |
Transaction in Own Shares
Lonza Completes its Share Buyback Program
|
English | 12.2 KB | |
| 2025-01-30 06:25 |
Earnings Release
Lonza Delivers Solid 2024 Performance with CER Sales in Line with Prior Year an…
|
English | 40.1 KB | |
| 2025-01-29 06:25 |
Earnings Release
Lonza Delivers Solid 2024 Performance with CER Sales in Line with Prior Year an…
|
English | 40.1 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-14 | N/A | Executive member | Buy | None | 147,442.00 CHF |
| 2025-03-13 | N/A | Executive member | Buy | None | 107,906.00 CHF |
| 2025-03-12 | N/A | Executive member | Buy | None | 146,239.00 CHF |
| 2025-03-11 | N/A | Executive member | Buy | None | 382,476.00 CHF |
| 2025-03-10 | N/A | Executive member | Buy | None | 771,722.40 CHF |
| 2025-03-07 | N/A | Executive member | Buy | None | 338,476.00 CHF |
| 2025-03-06 | N/A | Executive member | Buy | None | 313,416.00 CHF |
| 2025-02-18 | N/A | Executive member | Buy | None | 164,554.00 CHF |
| 2025-02-14 | N/A | Executive member | Buy | None | 130,606.00 CHF |
| 2025-02-13 | N/A | Executive member | Buy | None | 29,500.00 CHF |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Ascelia Pharma | Sweden | ACE | |
|
Atrys Health S.A. | Spain | ATRY | |
|
AUKETT SWANKE GROUP PLC | United Kingdom | AUK | |
|
Azorean - Aquatic Technologies S.A. | Portugal | MLAAT | |
|
Bachem Holding AG | Switzerland | BANB | |
|
Bavarian Nordic | Denmark | BAVA | |
|
BB Biotech AG | Switzerland | BION | |
|
BEEKS FINANCIAL CLOUD GROUP PLC | United Kingdom | BKS | |
|
BenevolentAI | United Kingdom | BAI | |
|
BerGenBio | Norway | BGBIO |